Thermo Fisher inks deal to expand Oncomine Dx

Thermo Fisher Scientific has signed agreements with Daiichi Sankyo and Takeda Pharmaceuticals designed to expand the clinical utility of the Oncomine Dx Target Test in support of clinical trials and drug development programs at the Japanese companies. The agreements will focus on validating additional biomarkers and gene variants on the test. Under the terms of the agreements, Thermo Fisher will retain worldwide commercialization rights for the test and will lead all filings of supplemental premarket approvals to seek approval from the FDA.